RT @OncLive: 🌟 Big breakthroughs in lung cancer care are happening—don’t miss your chance to catch it live in Cleveland!.Join @LukasDelasos….

RT @OncLive: 🎸 Cutting-edge science takes the stage!.Join @LukasDelasos of @ClevelandClinic at the OncLive Lung Cancer State of the Science….

RT @anantm: 🚨 New paper in @Nature_NPJ Precision Oncology!.We show that radiomics + pathomics improves prediction of recurrence in early NS….

RT @n8pennell: With an OS HR identical to KN 671 despite only 3 pre-op cycles, do we really need the adjuvant portion of perioperative trea….

RT @n8pennell: Artificial Intelligence and Machine Learning Innovations to Improve Design and Representativeness in Oncology Clinical Trial….

RT @StephenVLiu: Phase II TROPiCS-03 study of sacituzumab govitecan (TROP2 ADC) in previously treated #SCLC @JTOonline. RR 42% (35% in plat….

Congratulations to our incoming fellows!.

RT @n8pennell: 😊 Join us!

RT @n8pennell: I am pleased to share that I am running for the Board of Directors in the ASCO Election. Learn more about me and the 12 othe….

Thank you @IASLC for the opportunity to present our research on radiomic biomarkers to predict response to ICI rechallenge for recurrent NSCLC as an oral abstract at #WCLC24!! Very proud of our team's work in this space @anantm @n8pennell @jpssr2 @Maedezkn

RT @DrJNaidoo: #WCLC24 Presidential I. Ph III HARMONI-2 ivonescimab v pembro in PDL>1% NSCLC:.- 398pts.- PFS HR 0.51 (11.1 v 5.82 mPFS).- b….

RT @FordePatrick: With the goal of addressing a key clinical question, which pts w lung cancer may benefit from adjuvant immunotherapy afte….

RT @jrgralow: .@asco board member and chair of ASCO AI Task Force @dapattmd discusses newly released ASCO principles for responsible use of….

RT @StephenVLiu: Overview of outcomes with 1L osimertinib @JTOonline. At progression, continuation of osimertinib associated with shorter s….

RT @BMuthusamyMD: 🚨🚨.Folks involved with thoracic oncology - please take this IASLC survey, I'm part of the educational committee, and this….

RT @ThejusJay: Publication alert 📢.We use "#multiomics machine learning to study host-#microbiome interactions in early-onset vs average-on….

RT @jamecancerdoc: We are excited to welcome an outstanding group young doctors - as freshly minted Hematology and Medical Oncology Fellows….

RT @oncodaily: @jamecancerdoc @LukasDelasos @ClevelandClinic @CleClinicMD @n8pennell @ccfhemonc @CCF_IMCHIEFS We would like to inform you t….

RT @jamecancerdoc: Please join me in congratulating and welcoming @LukasDelasos new member of @ClevelandClinic Thoracic Oncology Program an….